A blue and red virus surrounded by other viruses.

Potential therapeutic agents and associated bioassay data for COVID-19 and related human coronavirus infections

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has led to several million confirmed cases and hundreds of thousands of deaths worldwide. To support the ongoing research and development of COVID-19 therapeutics, this report provides an overview of protein targets and corresponding potential drug candidates with bioassay and structure-activity relationship data found in the scientific literature and patents for COVID-19 or related virus infections.

Highlighted are several sets of small molecules and biologics that act on specific targets, including 3CLpro, PLpro, RdRp, S protein-ACE2 interaction, helicase/NTPase, TMPRSS2, and furin, which are involved in the viral life cycle or in other aspects of the disease pathophysiology.  We hope this report will be valuable to the ongoing drug repurposing efforts and the discovery of new therapeutics with the potential for treating COVID-19.

Read the full journal publication

Related CAS Insights

Highlights from the CAS Insights webinar on the pharmaceutical patent landscape

White immune cells attacking a large pink cancer cell on a red tissue surface.

New translational research in immuno-oncology may reach patients who do not respond to current therapies

Pharmaceutical capsule containing a glowing orange DNA helix on a dark circuit board background.

CAS Insights Report: Unlocking the future of pharmaceutical innovation through patent intelligence.

Gain new perspectives for faster progress directly to your inbox.